Raphael Pharmaceutical Inc. financial data

Symbol
RAPH on OTC
Location
Suite 105 5348 Vegas Dr., Las Vegas, NV
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.78 % -92.3%
Return On Assets -2.93K % -463%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 19.6M shares +4.95%
Common Stock, Shares, Outstanding 19.6M shares +4.95%
Entity Public Float 17.2M USD +71.6%
Common Stock, Value, Issued 196K USD +4.81%
Weighted Average Number of Shares Outstanding, Basic 19.6M shares +5.09%
Weighted Average Number of Shares Outstanding, Diluted 19.6M shares +5.09%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 586K USD +3.72%
General and Administrative Expense 867K USD -2.14%
Operating Income (Loss) -1.45M USD -0.14%
Nonoperating Income (Expense) -19K USD -90%
Net Income (Loss) Attributable to Parent -1.47M USD -0.75%
Earnings Per Share, Basic 0 USD/shares +14.3%
Earnings Per Share, Diluted 0 USD/shares +14.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20K USD -83.3%
Other Assets, Current 8K USD +33.3%
Assets, Current 28K USD -77.8%
Property, Plant and Equipment, Net 2K USD
Assets 30K USD -76.6%
Accounts Payable, Current 125K USD +81.2%
Accrued Liabilities, Current 375K USD +1400%
Liabilities, Current 1.08M USD +158%
Retained Earnings (Accumulated Deficit) -9.64M USD -18.9%
Stockholders' Equity Attributable to Parent -1.05M USD -261%
Liabilities and Equity 30K USD -76.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -209K USD -21.5%
Net Cash Provided by (Used in) Financing Activities 240K USD +4.35%
Net Cash Provided by (Used in) Investing Activities -1K USD
Common Stock, Shares Authorized 21M shares -58%
Common Stock, Shares, Issued 19.6M shares +4.95%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 57K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 20K USD -83.3%
Deferred Tax Assets, Valuation Allowance 1.54M USD +21.1%
Deferred Tax Assets, Gross 1.54M USD +21.1%
Payments to Acquire Property, Plant, and Equipment 1K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.97M USD +21.3%